REGULAR CONTENT
Final ID
624
Type
Educational Exhibit-Poster Only
Authors
D Brown1, M Weir1, J Baker1, I Shahin2, Z Collins3, R Gandhi4, M Sultenfuss5, A Abdel Aal6, G Siskin7, N Ruff8, S Ganguli9, S Peck10, J Meek11, M Matrana12, M Petroziello13, R Ryu14, S Mouli1, R O'Hara15, N Fidelman16, R Tong17, K Vaheesan18, F Banovac1
Institutions
1Vanderbilt University Medical Center, Nashville, TN, 2Dallas Methodist Medical Center, Dallas, TX, 3Kansas University Medical Center, Westwood, KS, 4Miami Cardiac and Vascular Institute, Miami, FL, 5Houston Methodist Hospital, Houston, TX, 6University of Alabama Birmingham, Birmingham, AL, 7Albany Medical Center, Albany, NY, 8Eubio Medical Communications, College Park, GA, 9Massachusetts General Hospital/Harvard Medical School, Boston, MA, 10Sanford Health, Sioux Falls, SD, 11University of Arkansas, Little Rock, AR, 12Ochsner Medical Center, New Orleans, LA, 13Roswell Park Memorial Institute, Buffalo, NY, 14University of Colorado Denver, Aurora, CO, 15University of Utah/Huntsman Cancer Center, Salt Lake City, UT, 16University Of California San Francisco, San Francisco, CA, 17Sutter Health, San Francisco, CA, 18Saint Louis University Hospital, Saint Louis, MO
Purpose
1) Educate the Interventional Radiology (IR) community about the Radiation-Emitting SIR-Spheres in Non-resectable Liver Tumor (RESIN) registry, an ongoing interventional oncology big data project. (2) Demonstrate data capture for the registry using a Research Electronic Data Capture (REDCAP) database. (3) Provide an update regarding recruitment and pathologies treated to date.
Materials & Methods
Yttrium-90 (90Y) is being increasingly used to treat both primary and metastatic unresectable liver cancer. Reported data is primarily single-center and retrospective, which limits publication impact. RESIN is a multi-center prospective registry with the goal of increasing big data publications within IR.
Results
The RESIN registry is capturing patient demographics, primary and secondary diagnoses, medical history, treatment details, laboratory measures, tumor markers, complications, and outcomes via a secure, online interface. Efficacy outcomes include time to progression and overall survival. Treatment details include 90Y alone as well as combinations of 90Y plus systemic and biologic therapies. Toxicities are being tracked using CTCAE v4. We will show how REDCAP allows easy exportation of data into graphical format and assists in formatting for statistical analysis. The selected sites for RESIN include both academic and private practice groups to capture a cross-section of real-world use of resin 90Y microspheres. We will review the 15 month to date patient recruitment with breakdown by pathologic entities toward the goals of larger data sets in common tumor types as well as more definitive evaluation of 90Y in less common tumors that may benefit from a locoregional approach.
Conclusions
RESIN represents a major foray for IR into the world of big data informatics. REDCAP is a useful tool to capture study related information and generate data to further integrate acceptance of intra-arterial therapies into systemic regimens for tumors that are less frequently referred to IR.
Final ID
624
Type
Educational Exhibit-Poster Only
Authors
D Brown1, M Weir1, J Baker1, I Shahin2, Z Collins3, R Gandhi4, M Sultenfuss5, A Abdel Aal6, G Siskin7, N Ruff8, S Ganguli9, S Peck10, J Meek11, M Matrana12, M Petroziello13, R Ryu14, S Mouli1, R O'Hara15, N Fidelman16, R Tong17, K Vaheesan18, F Banovac1
Institutions
1Vanderbilt University Medical Center, Nashville, TN, 2Dallas Methodist Medical Center, Dallas, TX, 3Kansas University Medical Center, Westwood, KS, 4Miami Cardiac and Vascular Institute, Miami, FL, 5Houston Methodist Hospital, Houston, TX, 6University of Alabama Birmingham, Birmingham, AL, 7Albany Medical Center, Albany, NY, 8Eubio Medical Communications, College Park, GA, 9Massachusetts General Hospital/Harvard Medical School, Boston, MA, 10Sanford Health, Sioux Falls, SD, 11University of Arkansas, Little Rock, AR, 12Ochsner Medical Center, New Orleans, LA, 13Roswell Park Memorial Institute, Buffalo, NY, 14University of Colorado Denver, Aurora, CO, 15University of Utah/Huntsman Cancer Center, Salt Lake City, UT, 16University Of California San Francisco, San Francisco, CA, 17Sutter Health, San Francisco, CA, 18Saint Louis University Hospital, Saint Louis, MO
Purpose
1) Educate the Interventional Radiology (IR) community about the Radiation-Emitting SIR-Spheres in Non-resectable Liver Tumor (RESIN) registry, an ongoing interventional oncology big data project. (2) Demonstrate data capture for the registry using a Research Electronic Data Capture (REDCAP) database. (3) Provide an update regarding recruitment and pathologies treated to date.
Materials & Methods
Yttrium-90 (90Y) is being increasingly used to treat both primary and metastatic unresectable liver cancer. Reported data is primarily single-center and retrospective, which limits publication impact. RESIN is a multi-center prospective registry with the goal of increasing big data publications within IR.
Results
The RESIN registry is capturing patient demographics, primary and secondary diagnoses, medical history, treatment details, laboratory measures, tumor markers, complications, and outcomes via a secure, online interface. Efficacy outcomes include time to progression and overall survival. Treatment details include 90Y alone as well as combinations of 90Y plus systemic and biologic therapies. Toxicities are being tracked using CTCAE v4. We will show how REDCAP allows easy exportation of data into graphical format and assists in formatting for statistical analysis. The selected sites for RESIN include both academic and private practice groups to capture a cross-section of real-world use of resin 90Y microspheres. We will review the 15 month to date patient recruitment with breakdown by pathologic entities toward the goals of larger data sets in common tumor types as well as more definitive evaluation of 90Y in less common tumors that may benefit from a locoregional approach.
Conclusions
RESIN represents a major foray for IR into the world of big data informatics. REDCAP is a useful tool to capture study related information and generate data to further integrate acceptance of intra-arterial therapies into systemic regimens for tumors that are less frequently referred to IR.